Flunarizine - Xenon Pharmaceuticals

Drug Profile

Flunarizine - Xenon Pharmaceuticals

Alternative Names: XEN007

Latest Information Update: 08 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Xenon Pharmaceuticals
  • Class Antiepileptic drugs; Antimigraines; Piperazines; Sedating antihistamines; Vascular disorder therapies
  • Mechanism of Action Calcium channel antagonists; Histamine H1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Migraine
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Migraine

Most Recent Events

  • 08 Jun 2018 Chemical structure information added
  • 30 May 2018 Flunarizine - Xenon Pharmaceuticals is available for licensing as of 30 May 2018. www.xenon-pharma.com (Xenon Pharmaceuticals pipeline, May 2018)
  • 07 Mar 2018 XEN 007 receives Orphan Drug status for Migraine in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top